Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering operating margin
Operating margin is operating income as a percentage of revenue.
Immuneering's operating margin for the twelve months ending Sep 30, 2023 was -12328770.8%. For fiscal 2022 it was -16325.8%, against -1629.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -16325.8% | −14696.6 |
| FY2021 | Dec 31, 2021 | -1629.2% | −890.2 |
| FY2020 | Dec 31, 2020 | -739.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -3073627.9% | −3067764.9 |
| Q3 FY2022 | Sep 30, 2022 | -34362.0% | −32590.0 |
| Q2 FY2022 | Jun 30, 2022 | -12334.4% | −11123.8 |
| Q1 FY2022 | Mar 31, 2022 | -7036.4% | −6202.9 |
| Q4 FY2021 | Dec 31, 2021 | -5863.0% | −4985.5 |
| Q3 FY2021 | Sep 30, 2021 | -1772.0% | −1127.4 |
| Q2 FY2021 | Jun 30, 2021 | -1210.7% | −460.6 |
| Q1 FY2021 | Mar 31, 2021 | -833.5% | – |
| Q4 FY2020 | Dec 31, 2020 | -877.6% | – |
| Q3 FY2020 | Sep 30, 2020 | -644.7% | – |
| Q2 FY2020 | Jun 30, 2020 | -750.1% | – |
See a number that looks wrong?